- Home
- AUTL
as 11-21-2024 4:00pm EST
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 1.1B | IPO Year: | 2018 |
| Target Price: | $10.20 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.69 - $7.45 | Next Earning Date: | 11-12-2024 |
| Revenue: | $10,091,000 | Revenue Growth: | 82.71% |
| Revenue Growth (this year): | 816.67% | Revenue Growth (next year): | 374.47% |
Latest Autolus Therapeutics plc News
AUTL Breaking Stock News: Dive into AUTL Ticker-Specific Updates for Smart Investing
TipRanks
3 days ago
Autolus Therapeutics upgraded to Buy from Neutral at Goldman Sachs
MT Newswires
4 days ago
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
Simply Wall St.
7 days ago
Autolus Therapeutics Third Quarter 2024 Earnings: US$0.31 loss per share (vs US$0.26 loss in 3Q 2023)
MT Newswires
7 days ago
Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13
GuruFocus.com
7 days ago
Syncona Ltd (LSE:SYNC) Half Year 2025 Earnings Call Highlights: Navigating Market Challenges ...
GuruFocus.com
9 days ago
Autolus Therapeutics PLC (AUTL) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Thomson Reuters StreetEvents
9 days ago
Q3 2024 Autolus Therapeutics PLC Earnings Call
GlobeNewswire
10 days ago
Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates
Compare AUTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AUTL Autolus Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.